BCMA and Beyond for CAR T Cell Therapy of MM

Share
Print

MM remains an incurable malignancy requiring novel strategies for treatment of relapsed disease. BCMA targeted CAR T cell therapies stemming from our group and others induce frequent and deep responses in heavily pre-treated patients with limited treatment options. Despite these encouraging results, relapses still occur commonly.  This lecture will address the development and results of BCMA targeted CAR T cell therapy, and approaches we are evaluating in the lab to address mechanisms of resistance limiting the durability of responses.

(Refreshments will be served at 9:45 am)

Date & Time(s)

Location

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
ZRC Auditorium
New York, NY 10065

Contact

For more information, please contact Emily Delgado delgadoe@mskcc.org

Host(s)

Human Oncology & Pathogenesis Program

Speaker(s)

Eric Smith, MD, PHD
Director of Translational Development
Cellular Therapeutics Center
Assistant Attending, Myeloma Service
Department of Medicine